166 related articles for article (PubMed ID: 36306337)
1. Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma.
Eertink JJ; Zwezerijnen GJC; Wiegers SE; Pieplenbosch S; Chamuleau MED; Lugtenburg PJ; de Jong D; Ylstra B; Mendeville M; Dührsen U; Hanoun C; Hüttmann A; Richter J; Klapper W; Jauw YWS; Hoekstra OS; de Vet HCW; Boellaard R; Zijlstra JM
Blood Adv; 2023 Jan; 7(2):214-223. PubMed ID: 36306337
[TBL] [Abstract][Full Text] [Related]
2.
Eertink JJ; van de Brug T; Wiegers SE; Zwezerijnen GJC; Pfaehler EAG; Lugtenburg PJ; van der Holt B; de Vet HCW; Hoekstra OS; Boellaard R; Zijlstra JM
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):932-942. PubMed ID: 34405277
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
4. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
Eertink JJ; Zwezerijnen GJC; Heymans MW; Pieplenbosch S; Wiegers SE; Dührsen U; Hüttmann A; Kurch L; Hanoun C; Lugtenburg PJ; Barrington SF; Mikhaeel NG; Ceriani L; Zucca E; Czibor S; Györke T; Chamuleau MED; Hoekstra OS; de Vet HCW; Boellaard R; Zijlstra JM
Blood; 2023 Jun; 141(25):3055-3064. PubMed ID: 37001036
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
6. Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?
Eertink JJ; Pfaehler EAG; Wiegers SE; van T; Brug D; Lugtenburg PJ; Hoekstra OS; Zijlstra JM; de Vet HCW; Boellaard R
J Nucl Med; 2022 Mar; 63(3):389-395. PubMed ID: 34272315
[TBL] [Abstract][Full Text] [Related]
7. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
8.
Cui Y; Jiang Y; Deng X; Long W; Liu B; Fan W; Li Y; Zhang X
Acad Radiol; 2023 Jul; 30(7):1408-1418. PubMed ID: 36437191
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
10. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
[TBL] [Abstract][Full Text] [Related]
11. Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features.
Eertink JJ; Zwezerijnen GJC; Cysouw MCF; Wiegers SE; Pfaehler EAG; Lugtenburg PJ; van der Holt B; Hoekstra OS; de Vet HCW; Zijlstra JM; Boellaard R
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4642-4651. PubMed ID: 35925442
[TBL] [Abstract][Full Text] [Related]
12. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
13. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the prognostic values of
Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134
[TBL] [Abstract][Full Text] [Related]
15. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
16. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Outcome Prediction via Baseline, End-of-Treatment, and Delta Radiomics on PET-CT Images of Primary Mediastinal Large B-Cell Lymphoma.
Yousefirizi F; Gowdy C; Klyuzhin IS; Sabouri M; Tonseth P; Hayden AR; Wilson D; Sehn LH; Scott DW; Steidl C; Savage KJ; Uribe CF; Rahmim A
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539425
[TBL] [Abstract][Full Text] [Related]
18. Inferior survival in high-grade B-cell lymphoma with
McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
